These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2281043)

  • 1. The development of USP dissolution and drug release standards.
    Cohen JL; Hubert BB; Leeson LJ; Rhodes CT; Robinson JR; Roseman TJ; Shefter E
    Pharm Res; 1990 Oct; 7(10):983-7. PubMed ID: 2281043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mini review of scientific and pharmacopeial requirements for the disintegration test.
    Donauer N; Löbenberg R
    Int J Pharm; 2007 Dec; 345(1-2):2-8. PubMed ID: 17935916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
    Williams RL; ;
    J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence studies for complex active ingredients and dosage forms.
    Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R
    AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral dosage form performance tests: new dissolution approaches.
    Hauck WW; Foster T; Sheinin E; Cecil T; Brown W; Marques M; Williams RL
    Pharm Res; 2005 Feb; 22(2):182-7. PubMed ID: 15783064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution test acceptance sampling plans.
    Tsong Y; Hammerstrom T; Lin K; Ong TE
    J Biopharm Stat; 1995 Jul; 5(2):171-83. PubMed ID: 7581426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of a novel in vitro discriminatory dissolution method for a class I drug in a matrix tablet formulation.
    Farrell C; Butler J; Stark P; Madden H; Devane J
    Adv Exp Med Biol; 1997; 423():217-20. PubMed ID: 9269498
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence.
    Miller DA; Gamba M; Sauer D; Purvis TP; Clemens NT; Williams RO
    Int J Pharm; 2007 Feb; 330(1-2):61-72. PubMed ID: 17034967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution testing of orally disintegrating tablets.
    Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
    J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
    Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.
    Brown CK; Friedel HD; Barker AR; Buhse LF; Keitel S; Cecil TL; Kraemer J; Morris JM; Reppas C; Stickelmeyer MP; Yomota C; Shah VP
    AAPS PharmSciTech; 2011 Jun; 12(2):782-94. PubMed ID: 21688063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.
    Deng G; Ashley AJ; Brown WE; Eaton JW; Hauck WW; Kikwai LC; Liddell MR; Manning RG; Munoz JM; Nithyanandan P; Glasgow MJ; Stippler E; Wahab SZ; Williams RL
    Pharm Res; 2008 May; 25(5):1100-9. PubMed ID: 18172581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inferential procedure for the probability of passing the USP dissolution test.
    Chiang C; Chen CF; Huang MY; Liu JP
    Pharm Stat; 2012; 11(1):32-8. PubMed ID: 21506255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel off-center paddle impeller (OPI) dissolution testing system for reproducible dissolution testing of solid dosage forms.
    Wang Y; Armenante PM
    J Pharm Sci; 2012 Feb; 101(2):746-60. PubMed ID: 22083630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro.
    Case CL; Henniges F; Barkin JS
    Pancreas; 2005 Mar; 30(2):180-3. PubMed ID: 15714141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro development of extended-release solid oral dosage forms.
    Leeson LJ; Adair D; Clevenger J; Chiang N
    J Pharmacokinet Biopharm; 1985 Oct; 13(5):493-514. PubMed ID: 3834065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.